Research programme: insulin based therapeutics - Albireo Pharma

Drug Profile

Research programme: insulin based therapeutics - Albireo Pharma

Alternative Names: BIOD-104; BIOD-620; BIOD-Glucose-responsive Basal; BIOD-Smart Basal; Glucose-sensing basal insulin; Injectable smart basal insulin; Vialog

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Biodel
  • Developer Albireo Pharma
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 18 Nov 2014 Biodel has patent protection for its ultra-rapid-acting insulin formulations in Europe
  • 08 May 2013 Biodel selects BIOD 531 as a lead concentrated ultra-rapid-acting insulin product candidate for Diabetes mellitus
  • 26 Jul 2012 Biodel receives SBIR grant from the National Institutes of Health for the development of concentrated, ultra-rapid-acting insulin formulation for use with artificial pancreas in diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top